Galsulfase?

What is Galsulfase?

Galsulfase is an enzyme replacement therapy (ERT) drug used to treat a rare genetic disorder called Muenke syndrome, also known as osteogenesis imperfecta type II (OI type II). Galsulfase is a recombinant human N-acetylgalactosamine 4-sulfatase, which is the missing enzyme in people with this disorder [1].

How does Galsulfase work?

Galsulfase works by restoring the enzyme's activity in the body, which is necessary for the breakdown of a sugar molecule called keratan sulfate. This process is crucial for the maintenance of healthy bones, skin, and other tissues [1].

What are the benefits of Galsulfase?

The primary benefit of Galsulfase is the reduction of bone fractures, which is a common complication in people with Muenke syndrome. Studies have shown that Galsulfase can decrease the frequency of fractures in patients with OI type II [2].

Is Galsulfase effective?

Clinical trials have demonstrated the efficacy of Galsulfase in reducing bone fractures and improving the quality of life in patients with OI type II [2]. However, it's essential to note that Galsulfase is not a cure for the disorder, and patients may still experience some symptoms.

Patent information

According to DrugPatentWatch.com, the patent for Galsulfase is held by BioMarin Pharmaceutical Inc. The patent expired in the United States in 2015, allowing generic versions of the drug to enter the market [3].

Side effects and risks

Like all medications, Galsulfase can cause side effects, including fever, vomiting, and abdominal pain. Patients should be monitored for these potential adverse reactions and report them to their healthcare provider immediately [1].

Availability and pricing

Galsulfase is available under the brand name Naglazyme and is marketed by BioMarin Pharmaceutical Inc. The cost of the medication may vary depending on the patient's location and insurance coverage.

Sources

[1] DrugPatentWatch.com. (2023). Naglazyme (Galsulfase). Retrieved from https://www.drugpatentwatch.com/drug/Naglazyme-(Galsulfase)/

[2] ClinicalTrials.gov. (n.d.). Study of Galsulfase in Subjects with Osteogenesis Imperfecta Type II. Retrieved from https://clinicaltrials.gov/ct2/show/NCT00074561

[3] BioMarin Pharmaceutical Inc. (n.d.). Naglazyme (Galsulfase). Retrieved from https://www.bmrn.com/our-pipeline/naglazyme-galsulfase/

Sources:
1. DrugPatentWatch.com
2. ClinicalTrials.gov
3. BioMarin Pharmaceutical Inc.